Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | CASP3 | P42574 | 1/20 | 0.47 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1665636 | 0.82 | SMN1; SMN2 (0.60) | TSHRSMN1; SMN2CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL23962408 | 0.79 | TSHR (0.57) | TSHRPOLBSMN1; SMN2CYP1A2CYP2C9 | |
| SCHEMBL1665851 | 0.78 | FAAH (0.37) | — | |
| SCHEMBL6224279 | 0.78 | ERN1 (0.54) | TSHRPOLBSMN1; SMN2KDM4E | |
| SCHEMBL26426497 | 0.75 | TSHR (0.62) | TSHRPOLBSMN1; SMN2CYP1A2CYP2C9 | |
| SCHEMBL1665144 | 0.75 | CYP1A2 (0.68) | TSHRSMN1; SMN2CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL1665131 | 0.74 | TP53 (0.55) | TSHRPOLBSMN1; SMN2CYP1A2CYP2C9 | |
| SCHEMBL4599565 | 0.72 | EPHX1 (0.68) | TSHRSMN1; SMN2CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL3511959 | 0.72 | TSHR (0.52) | TSHRPOLBSMN1; SMN2CYP1A2CYP2C9 | |
| SCHEMBL1665123 | 0.71 | TP53 (0.51) | TSHRPOLBSMN1; SMN2CYP1A2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2493905-B1 | BISPHOSPHONATE COMPOUNDS FOR TREATING BONE METABOLISM DISORDERS | WARNER CHILCOTT CO LLC (PR) | 2016-11-30 | — | — | EP | disclosed |
| EP-2493905-B1 | BISPHOSPHONATE COMPOUNDS FOR TREATING BONE METABOLISM DISORDERS | WARNER CHILCOTT CO LLC (PR) | 2016-11-30 | — | — | EP | disclosed |
| US-8822435-B2 | Bisphosphonate compounds | WARNER CHILCOTT COMPANY, LLC (US) | 2014-09-02 | — | — | US | disclosed |
| US-8822435-B2 | Bisphosphonate compounds | WARNER CHILCOTT COMPANY, LLC (US) | 2014-09-02 | — | — | US | disclosed |
| US-8822435-B2 | Bisphosphonate compounds | WARNER CHILCOTT COMPANY, LLC (US) | 2014-09-02 | — | — | US | disclosed |
| US-20140194389-A1 | BISPHOSPHONATE COMPOUNDS | WARNER CHILCOTT COMPANY, LLC (US) | 2014-07-10 | — | — | US | disclosed |
| US-20140194389-A1 | BISPHOSPHONATE COMPOUNDS | WARNER CHILCOTT COMPANY, LLC (US) | 2014-07-10 | — | — | US | disclosed |
| US-20140194389-A1 | BISPHOSPHONATE COMPOUNDS | WARNER CHILCOTT COMPANY, LLC (US) | 2014-07-10 | — | — | US | disclosed |
| US-8710215-B2 | Bisphosphonate compounds | WARNER CHILCOTT COMPANY, LLC (US) | 2014-04-29 | — | — | US | disclosed |
| US-8710215-B2 | Bisphosphonate compounds | WARNER CHILCOTT COMPANY, LLC (US) | 2014-04-29 | — | — | US | disclosed |
| US-20130035482-A1 | BISPHOSPHONATE COMPOUNDS | WARNER CHILCOTT COMPANY, LLC (US) | 2013-02-07 | — | — | US | disclosed |
| US-8314081-B2 | Bisphosphonate compounds | WARNER CHILCOTT COMPANY, LLC (US) | 2012-11-20 | — | — | US | disclosed |
| US-8314081-B2 | Bisphosphonate compounds | WARNER CHILCOTT COMPANY, LLC (US) | 2012-11-20 | — | — | US | disclosed |
| US-8314081-B2 | Bisphosphonate compounds | WARNER CHILCOTT COMPANY, LLC (US) | 2012-11-20 | — | — | US | disclosed |
| EP-2493905-A1 | BISPHOSPHONATE COMPOUNDS FOR TREATING BONE METABOLISM DISORDERS | Warner Chilcott Company, LLC (PR) | 2012-09-05 | — | — | EP | disclosed |
| WO-2011056589-A1 | BISPHOSPHONATE COMPOUNDS FOR TREATING BONE METABOLISM DISORDERS | WARNER CHILCOTT COMPANY, LLC (US) | 2011-05-12 | — | — | WO | disclosed |
| WO-2011056589-A1 | BISPHOSPHONATE COMPOUNDS FOR TREATING BONE METABOLISM DISORDERS | WARNER CHILCOTT COMPANY, LLC (US) | 2011-05-12 | — | — | WO | disclosed |
| US-20110098251-A1 | BISPHOSPHONATE COMPOUNDS | WARNER CHILCOTT COMPANY, LLC (US) | 2011-04-28 | — | — | US | disclosed |
| US-20110098251-A1 | BISPHOSPHONATE COMPOUNDS | WARNER CHILCOTT COMPANY, LLC (US) | 2011-04-28 | — | — | US | disclosed |
| US-20110098251-A1 | BISPHOSPHONATE COMPOUNDS | WARNER CHILCOTT COMPANY, LLC (US) | 2011-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140194389-A1 | BISPHOSPHONATE COMPOUNDS | BPGM, PPIP5K2, PTEN | TSHR 3291/4885POLB 2835/4885SMN1; SMN2 2670/4885 |
| US-20110098251-A1 | BISPHOSPHONATE COMPOUNDS | BPGM, PPIP5K2, PTEN | TSHR 3291/4885POLB 2835/4885SMN1; SMN2 2670/4885 |
| US-20130035482-A1 | BISPHOSPHONATE COMPOUNDS | BPGM, PPIP5K2, PTEN | TSHR 3291/4885POLB 2835/4885SMN1; SMN2 2670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.